Jansen W, Seibel K, Bühling M
Arzneimittelforschung. 1985;35(7):1080-3.
An open and a placebo-controlled double-blind trial were carried out to measure the effect of a long-term treatment (2-6 months) with etilefrine pivalate (K 30 052, Ep) on blood pressure of 60 patients suffering from orthostatic dysregulation. Oral administration of the agent took place once daily, each dose containing 20 mg. While the acute response to a single dose was comparatively weak, long-term administration had a marked and long-lasting effect both on systolic blood pressure (+40.3 mmHg) and blood pressure amplitude (+37.5 mmHg) (p less than 0.01). Steady state values were reached only when duration of therapy was approaching 6 months. The increase in blood pressure amplitude points to an augmentation of stroke volume, whereas heart rate was virtually unaltered. Peripheral resistance appears not to be increased since diastolic pressure was unchanged. The elevation in blood pressure amplitude was fully reversible within 9 weeks of wash-out, thus hinting at functional rather than structural (sclerotic) changes in the cardiovascular system.
进行了一项开放试验和一项安慰剂对照双盲试验，以测定长期（2 - 6个月）服用新戊酸乙苯福林（K 30 052，Ep）对60例体位性调节障碍患者血压的影响。该药物每日口服一次，每次剂量含20毫克。虽然单次剂量的急性反应相对较弱，但长期给药对收缩压（+40.3 mmHg）和血压幅度（+37.5 mmHg）均有显著且持久的影响（p小于0.01）。仅当治疗持续时间接近6个月时才达到稳态值。血压幅度的增加表明心搏量增加，而心率几乎未改变。由于舒张压未变，外周阻力似乎没有增加。血压幅度的升高在停药9周内完全可逆，因此提示心血管系统的变化是功能性而非结构性（硬化性）的。
